Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1160/TH07-06-0396 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First use of F-FDG PET in TEMPI syndrome: can it be used for treatment assessment? A case report.
Front Nucl Med
October 2023
Nuclear Medicine Department, CHRU TOURS, Tours, France.
Article Synopsis
- TEMPI syndrome combines features like telangiectasias, polycythemia with high erythropoietin levels, monoclonal gammopathy, and has a link to plasma cell neoplasms, but its exact cause is still unclear.
- The use of F-FDG PET imaging is valuable for initial evaluation and treatment monitoring in conditions like multiple myeloma and has been applied successfully for a TEMPI patient, showing significant treatment responses.
- In a 51-year-old woman, post-treatment F-FDG PET scans indicated complete reduction of bone lesions and normalization of symptoms, suggesting the effectiveness of the treatment and the potential of F-FDG PET in managing TEMPI syndrome.
Modulation of angiogenic switch in reprogramming browning and lipid metabolism in white adipocytes.
Biochim Biophys Acta Mol Cell Biol Lipids
January 2024
Biological Materials Laboratory, Council of Scientific and Industrial Research - Central Leather Research Institute, Chennai, Tamil Nadu 600020, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address:
Thermogenic activation via trans-and de novo browning of white adipocytes is a promising strategy to accelerate lipid metabolism for regulating obesity-related disorders. In this study, we investigated the intricate interplay between angiogenic regulation and browning in white adipocytes using the bioactive compound, resveratrol (Rsv). Rsv has previously been documented for its regulatory influence on the trans and de novo browning of white adipocytes.
View Article and Find Full Text PDFA Landmark Paper That Introduced Proteasome Inhibition in Myeloma.
Cancer Res
October 2023
Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
The ongoing therapeutic revolution in multiple myeloma care can be traced to the turn of the millennium with the unanticipated discovery in 1999 that the cereblon binding small molecule thalidomide had profound clinical effectiveness and, simultaneously, the emergence of a new class of targeted therapies inhibiting the proteasome, both of which ultimately target ubiquitinated protein degradation. These contemporaneous discoveries forever changed the landscape of multiple myeloma care, substantially extending survival. Foreshadowing this seismic change, Nobel Prize winning work on the proteasome ubiquitin pathway had stimulated the development of highly specific proteasome inhibitor small molecules, particularly PS-341 (later named bortezomib).
View Article and Find Full Text PDFEfficacy of concurrent chemoradiotherapy with thalidomide and S-1 for esophageal carcinoma and its influence on serum tumor markers.
World J Gastrointest Oncol
July 2023
Department of Hematology and Radiotherapy, Zibo 148 Hospital, Zibo 255300, Shandong Province, China.
Background: Although the current conventional treatment strategies for esophageal carcinoma (EC) have been proven effective, they are often accompanied by serious adverse events. Therefore, it is still necessary to continue to explore new therapeutic strategies for EC to improve the clinical outcome of patients.
Aim: To elucidate the clinical efficacy of concurrent chemoradiotherapy (CCRT) with thalidomide (THAL) and S-1 (tegafur, gimeracil, and oteracil potassium capsules) in the treatment of EC as well as its influence on serum tumor markers (STMs).
Thalidomide Attenuates Mast Cell Activation by Upregulating SHP-1 Signaling and Interfering with the Action of CRBN.
Cells
February 2023
Department of Pharmacology, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea.
Allergy is a chronic inflammatory disease, and its incidence has increased worldwide in recent years. Thalidomide, which was initially used as an anti-emetic drug but was withdrawn due to its teratogenic effects, is now used to treat blood cancers. Although the anti-inflammatory and immunomodulatory properties of thalidomide have been reported, little is known about its influence on the mast cell-mediated allergic reaction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!